Marcadia Biotech

Next-generation incretin peptide therapeutics for type 2 diabetes

Marcadia was a spinout from The University of Indiana that focused on novel diabetes therapeutics. The company's programs were based on novel insights into the incretin pathways (GLP-1, GIP, glucagon) from the lab of Richard DiMarchi, and the company formed multiple partnerships with Merck and Eli Lilly for these assets. Marcadia was acquired in 2010 by Roche.

Status
Acquired by Roche in 2010
Year of Investment
2007
Strategy
Life Sciences
Location
Carmel, Indiana